海特生物：10月22日召开董事会会议

Group 1 - The core point of the article is that Hite Bio (SZ 300683) held its fifth meeting of the ninth board of directors on October 22, 2025, where it reviewed documents including the "Audit Committee Work Rules" [1] - For the first half of 2025, Hite Bio's revenue composition was as follows: 51.82% from pharmaceutical technology services, 37.87% from biopharmaceuticals, 9.49% from raw materials and pharmaceutical intermediates, 0.7% from in vitro diagnostic reagents, and 0.11% from other industries [1] - As of the report date, Hite Bio's market capitalization was 4.5 billion yuan [1]